CM
About
Cogentix Medical products have increased treatment efficiency and lowered patient risk. Macroplastique® established the European market for bulking agents, EndoSheath® protective barrier redefined endoscopy and Urgent® PC set the standard for percutaneous tibial nerve stimulation (PTNS) as a treatment for Overactive Bladder. Cogentix Medical was formed in 2015 following a merger of Uroplasty and Vision-Sciences.
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 12 investors are based in Minnesota City, Minnesota, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech biotech
- Location
- Minnesota City, US
Contact Information
Find more investors like Cogentix
Search Investors